William Kaelin Jr elected to Lilly board
pharmafile | June 6, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Cancer, Kaelin, lilly
Eli Lilly has elected William Kaelin Jr to its board of directors.
Dr Kaelin, 54, is a Professor in the Department of Medicine at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, senior physician at Brigham and Women’s Hospital, and associate director, Basic Science, at the Dana-Farber/Harvard Cancer Center.
As a member of Lilly’s board, Kaelin will serve on the science and technology committee and the finance committee. He will serve under interim election to fill a vacancy left by the retirement of Dr Martin Feldstein and will stand for election by Lilly shareholders at the company’s annual meeting in May, 2014.
“I am very pleased to welcome Dr Bill Kaelin to the Lilly board. Dr Kaelin’s deep scientific knowledge and medical expertise will benefit Lilly shareholders and the patients who depend on us,” commented John Lechleiter, Lilly chairman, president and chief executive.
“Bill is a leading cancer researcher and has a clear appreciation of the importance of scientific research and of Lilly’s commitment to the discovery and development of innovative medicines that make a difference for patients.”
Kaelin received his medical degree from Duke University in 1982 and was a house officer in internal medicine at Johns Hopkins Hospital. He went on to become a medical oncology clinical fellow at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of Dr David Livingston, where he began his studies of tumour suppressor proteins.
The long-term goal of his work is to lay the foundation for the development of new anticancer therapies based on the functions of specific tumour suppressor proteins.
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
T-cell therapy – the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds
